---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117179"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:06:00.251456+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics reports Q3 net loss $0.7M; FDA meeting on IV Tramadol and acquisition of Baergic Bio

## Summary
- Q3 2022 net loss $0.7M ($0.45/share) vs $0.9M ($0.79/share) in Q3 2021.
- Cash $0.2M at Sep 30, 2022 (down from $3.8M at Dec 31, 2021); then raised ~$10.4M net in October offering.
- FDA agreed proposed IV Tramadol study design appears reasonable; detailed protocol submission planned.
- Completed acquisition of Baergic Bio, adding BAER-101 (GABA-A α2/3 PAM) for refractory epilepsies and panic disorders.
- Effected 1-for-15 reverse stock split and closed $12M public offering; regained Nasdaq compliance.

## SEC filing metadata
- accession: 0001104659-22-117179
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465922117179/0001104659-22-117179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465922117179/tm2230162d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117179
- JSON: https://secwatch.observer/filing/0001104659-22-117179.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117179.txt

## Key facts
- Earnings Releases
  AVENUE THERAPEUTICS, INC. reported the third quarter ended September 30, 2022 results: net income Net loss attributable to common stockholders for the third quarter of 2022 was $0.7 million, or $0.45 per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: Net loss attributable to common stockholders for the third quarter of 2022 was $0.7 million, or $0.45 per share
  - Result: reported results
  source text: Avenue Therapeutics, Inc. (the “Company” or “Avenue”) issued a press release to provide a corporate update and to announce its financial results for the three months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465922117179/0001104659-22-117179-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.